On July 26, Shenzhen Development and Reform Commission issued a series of "Several measures to promote the high-quality development of biomedical industry clusters in Shenzhen", "Several measures to promote the high-quality development of high-end medical device industry clusters in Shenzhen", "Several measures to promote the high-quality development of large health industry clusters in Shenzhen" Measures"Three documents, the heavy policy is intended to support the biomedicine and general health industry.

Among them, in "Several Measures for Shenzhen to Promote the High-quality Development of Big Health Industry Clusters"The relevant cell industry support policies are as follows:

Three, vigorously promote the development of precision medicine industry

(6) Create a new highland for the gene and immune cell therapy industry. Support enterprises, scientific research institutions, and medical institutions to carry out industry-university-research cooperation, and support major theories, original technologies, and cutting-edge interdisciplinary studies in gene and immune cell therapy. Basic research, striving to achieve major technological breakthroughs and original discoveries in the fields of gene editing, gene therapy, and immune cell therapy. Support clinical trials and investigator-initiated clinical studies in the fields of gene therapy and immune cell therapy, with a focus on exploring Tumor, cardiovascular and cerebrovascular diseases and diabetes, immunodeficiency diseases, chronic disease gene therapy and immune cell therapy.

(7) Cultivate and develop new formats such as stem cells. Support the application for national-level qualifications for new stem cell technologies, clinical transformation of new products, and pilot programs for promotion and application. Focus on basic research on hematopoietic stem cells, umbilical cord mesenchymal stem cells, stored umbilical cord mesenchymal stem cells, and pluripotent stem cells. Encourage the filing of stem cell clinical research institutions and projects, and accelerate the promotion of stem cell and regenerative medicine industry health in our city develop. For those who have obtained the municipal cell bank qualification, 40% of the total project investment will be funded, with a maximum of 30 million yuan.

(8) Build a world-class health management system. Vigorously develop the health management industry focusing on health consultation, health testing, health intervention, chronic disease management, family doctor, health insurance, etc. Establish mental rehabilitation, psychological treatment, health check-up, early disease screening and other institutions to provide occupational disease health management services.

(9) Support the construction of a cell and gene biosafety testing platform. Approved by the American Association of Blood Banks (AABB) or Laboratory Accreditation (CMA) or accredited by the China National Accreditation Service for Conformity Assessment ( CNAS), a third-party inspection and testing agency for cell and gene safety assessment and inspection platform, the best ones will be funded according to 40% of the total project investment, with a maximum of no more than 5 million yuan.

The "Several Measures to Promote the High-Quality Development of Biomedical Industry Clusters in Shenzhen" issued this time also highlighted cell therapy drugs, gene therapy drugs, etc. In the field, will realize the full link support of biomedicine from basic, clinical to marketing.

This will be accelerated by The construction of the infrastructure of the pharmaceutical industry, the strengthening of the transformation capacity of drug clinical research, the acceleration of the drug registration approval process, and the increased support for the R&D and production of pharmaceutical companies, etc., For products and platform projects with high technical content, good application prospects, and strong demonstration and driving effects, priority will be given to support in terms of financial support, land and housing, talent incentives, registration approval, and government services.

✦Accelerate the construction of pharmaceutical industry infrastructure

Support the construction of national key laboratories, national engineering research centers and other national innovation carriers in Shenzhen, support the construction of deep Shenzhen's National Enterprise Technology Center provides funding for those who take the initiative to undertake major national development strategic tasks such as new drug research and development, as well as those who take the initiative to undertake key technological breakthroughs and major industrial projects such as genetic drugs and cell products.

✦Strengthen the translation ability of drug clinical research

Strengthen the incentives for drug clinical research, improve the support platform system for drug clinical research, explore the mutual recognition of the results of ethical review of clinical research in medical institutions, and effectively reduce clinical trials Repeat approval, shorten the research and development cycle of innovative products, and encourage the development of drug clinical trial services.

✦Accelerating the drug registration approval process

Train high-quality drug testing technicians, improve drug testing and testing capabilities, strengthen review and inspection consulting services, and explore the promotion of real-world data applications in clinical evaluation to accelerate product launch.

✦Increase support for R&D and production of pharmaceutical companies

Support the research and development of innovative drugs, support the development of overseas pharmaceutical markets, promote the industrialization of innovative drug achievements, and promote the application of innovative pharmaceutical products.

The relevant policies issued by the Shenzhen Development and Reform Commission this time are to consolidate the development goals proposed for the cell and gene industry, that is, by 2025, the cell and gene industry will experience explosive growth. Growth, industrial development focuses on the development of cell technology, gene technology, cell and gene therapy technology, biological breeding technology, etc. It is expected to become a strategic emerging industry within 5 to 10 years.